Connect your agent to akta.pro and build company lists like this across sectors and geos.
Fifteen US-listed biotech companies that reported a failed, missed or halted clinical trial in 2026, ranked by editorial relevance.
— 12 of 15 companies are headquartered in two states: California with 7 and Massachusetts with 5 — The rest are Regeneron and Immunovant in New York and Summit in Miami.
— Gossamer Bio's 80% one-day fall was the steepest, ahead of MapLight at more than 70% — Both followed a Phase 3 or Phase 2 trial that fell narrowly or partly short of its primary endpoint.
— 5 of the 15 reported Phase 3 failures: Gossamer, Neumora, Vistagen, Regeneron and Ionis — Ionis's two failures were in partner-run trials, run by AstraZeneca and Novartis.
Top HQ state California7 of 15 companies.
Distinct incidents 15After consolidating duplicate and follow-up coverage.
Steepest one-day drop 80%Gossamer Bio, on February 23, 2026.
Editorial list Coverage: United States, US biotech companies Filter: Negative sentiment Window: Jan 1, 2026 – Oct 26, 2026 Ranked by: Incident relevance Source: akta.pro News Signals Compiled: Oct 26, 2026| # | Company name | Firmographics | Funding & investors | What company does | What happened & why | Sources |
|---|---|---|---|---|---|---|
| 01 | Ionis Pharmaceuticals ionispharma.com Critical | Founded 1989 Carlsbad, North America USA | $2.45B Last raise 2025 | Carlsbad developer of RNA-targeted medicines. Antisense Oligonucleotides (ASO) Therapeutics (splice modulation/knockdown) | Two partnered Phase 3 trials missed their primary endpoints: AstraZeneca's Wainua trial in heart disease on July 9, 2026, and Novartis's pelacarsen… Why Coverage reports both misses and gives no cause; both trials were run by its partners. | 40 sources · 27 outlets |
| 02 | Regeneron regeneron.com Critical | Founded 1988 Tarrytown, North America USA | $16M Last raise 2024 | Tarrytown biotechnology company. | Its fianlimab melanoma combination missed the Phase 3 progression-free survival goal in May 2026, and it ended a Phase 1/2 uveitis study of REGN7041… Why It ended the uveitis study on an unfavorable benefit-risk assessment after a safety event; coverage gives no cause for the melanoma miss. | 38 sources · 26 outlets |
| 03 | Immunovant immunovant.com Critical | Founded 2018 New York, North America USA | $1.86B Public | New York developer of monoclonal antibody therapies. Monoclonal Antibody Therapeutics (mAbs) | Discontinued its cutaneous lupus program on September 23, 2026, after a Phase 2b trial of IMVT-1402 missed its primary endpoint; shares fell about 7%. Why The 57-patient trial did not reach statistical significance. | 16 sources · 11 outlets |
| 04 | Biogen biogen.com Critical | Founded 1978 Cambridge, North America USA | $1.50B Last raise 2023 | Cambridge neuroscience-focused biotechnology company. Neurology & Psychiatry (CNS) Pharmaceuticals | Biogen and Denali discontinued their Parkinson's LRRK2 drug after the trial failed, reported May 21, 2026, and the shares slid. Why Coverage reports the trial failure and gives no cause. | 32 sources · 23 outlets |
| 05 | Agios Pharmaceuticals agios.com Critical | Founded 2008 Cambridge, North America USA | $776M Last raise 2019 | Cambridge developer of drugs for rare blood diseases. Hematology Specialty Pharmaceuticals (Non-malignant) | Abandoned its sickle cell candidate tebapivat on July 21, 2026, after Phase 2 data missed the hemoglobin response endpoint; shares fell as much as… Why Coverage says the data did not differentiate it from competing drugs, including its own mitapivat. | 17 sources · 12 outlets |
| 06 | Evommune evommune.com Critical | Founded 2020 Palo Alto, North America USA | $475M Last raise 2026 | Palo Alto developer of immunology drugs. Immunology & Inflammation Pharmaceuticals | EVO756 missed its primary endpoint in a Phase 2b atopic dermatitis trial on September 9, 2026, and shares fell about 17%. Why Coverage notes no symptom change and elevated liver enzymes, and that the drug had already failed in hives. | 21 sources · 14 outlets |
| 07 | Aardvark Therapeutics aardvarktherapeutics.com Critical | Founded 2017 San Diego, North America USA | $129M Last raise 2024 | San Diego developer of small-molecule therapies. | The FDA placed a full clinical hold on ARD-101 on May 15, 2026, when shares fell 32%, and the company terminated its Phase 3 trial in June. Why Coverage cites a cardiac safety signal, QRS prolongation. | 14 sources · 10 outlets |
| 08 | Neumora Therapeutics neumoratx.com Critical | Founded 2020 Watertown, North America USA | $615M Last raise 2024 | Watertown neuroscience drug developer. Neurology & Psychiatry (CNS) Pharmaceuticals | Navacaprant failed two more Phase 3 trials on June 15, 2026, and was discontinued; the company cut about 35% of its staff. Why The drug matched placebo in both KOASTAL-2 and KOASTAL-3. | 8 sources · 8 outlets |
| 09 | Summit Therapeutics smmttx.com Critical | Founded 2003 Miami, North America USA | $3.79B Last raise 2026 | Miami developer of ivonescimab, a drug licensed from Akeso. Antibody-Drug Conjugates (ADCs) & Antibody Conjugates | An interim trial miss for its PD-1xVEGF drug surprised analysts on May 1, 2026, and shares tumbled; questions followed in August over a narrowing… Why Coverage reports the miss and the narrowing benefit and gives no further cause. | 11 sources · 10 outlets |
| 10 | MapLight Therapeutics maplightrx.com Critical | Founded 2018 Redwood City, North America USA | $791M Last raise 2026 | Redwood City developer of central nervous system therapies. Neurology & CNS Specialty Pharmaceuticals | Shares fell more than 70% on July 27, 2026, after a Phase 2 schizophrenia trial in which only the twice-daily dose met the primary endpoint. Why Coverage says the effect size fell short of competitor Cobenfy. | 10 sources · 9 outlets |
| 11 | Gossamer Bio gossamerbio.com Critical | Founded 2017 San Diego, North America USA | $902M Last raise 2026 | San Diego developer of an inhaled pulmonary hypertension therapy. Pulmonary Hypertension & Rare Pulmonary Disease Therapies | Seralutinib narrowly missed the Phase 3 PROSERA primary endpoint on February 23, 2026, and shares fell 80%. Why The placebo-adjusted gain of about 13 meters in six-minute walk distance fell just short of the pre-specified threshold. | 10 sources · 9 outlets |
| 12 | Alector alector.com Critical | Founded 2013 South San Francisco, North America USA | $320M Last raise 2026 | South San Francisco neurodegenerative disease therapeutics company. Enzyme Replacement & Metabolic Disorder Therapies | Halted its Phase 2 PROGRESS-AD trial on April 30, 2026, its third neuro failure in 18 months, and GSK ended their partnership on July 9. Why An independent monitoring board found the drug unlikely to show efficacy. | 9 sources · 8 outlets |
| 13 | VistaGen vistagen.com Critical | Founded 1998 South San Francisco, North America USA | $155M Last raise 2026 | South San Francisco developer of an anxiety nasal spray. Neurology & CNS Specialty Pharmaceuticals | Its Phase 3 PALISADE-4 trial of fasedienol missed the primary endpoint on June 30, 2026, and a Phase 2 study failed on August 6. Why The drug showed no significant improvement over placebo. | 11 sources · 7 outlets |
| 14 | Compass Therapeutics compasstherapeutics.com Critical | Founded 2014 Boston, North America USA | $502M Last raise 2025 | Boston oncology antibody developer. Bispecific & Multispecific Antibodies | Its Phase 2/3 trial of tovecimig missed overall survival in April 2026, and on September 22 the FDA recommended a new trial, with shares down about… Why The drug met response and progression-free survival targets but not overall survival. | 9 sources · 7 outlets |
| 15 | Praxis Precision Medicines praxismedicines.com Critical | Founded 2015 Boston, North America USA | $1.67B Last raise 2026 | Boston developer of epilepsy and neurology drugs. Rare Neurology & Neurodegenerative Disorder Therapies | Its Phase 2/3 POWER1 trial of vormatrigine missed the primary endpoint on June 1, 2026, and it halted a second trial. Why Coverage says seizure reduction fell short of expectations. | 7 sources · 6 outlets |
A clinical trial failure is a study that does not meet its primary endpoint, is stopped for futility or safety, or whose program is discontinued afterwards. For a small biotech that depends on one lead drug, a failure can erase most of its market value in a day.
akta.pro has no category specific to trial failures, so this page uses the Research, Development & Innovation and Regulatory Approvals categories with negative sentiment, and then keeps only companies with a reported trial failure.
The companies here develop drugs for neurology, oncology, immunology, rare disease and cardiovascular conditions.
Included only where a 2026 headline reports a failed, missed, halted or discontinued clinical trial at a US-headquartered biotech. FDA rejections without a trial failure and diagnostics studies are out of scope.
NAICS and SIC are global standard industry classifications, shown as returned by akta.pro Company Data for the listed companies. The internal taxonomy is akta.pro's own industry tree: each code links to its akta.pro industry page, and the signal categories this page filters on are listed in the provenance line above.